The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1161-1167

  Boyd, Mark A ^a,b,c   Siangphoe, Umaporn ^a   Ruxrungtham, Kiat ^a,d   Reiss, Peter ^a,e   Mahanontharit, Apicha ^a   Lange, Joep M A ^a,e   Phanuphak, Praphan ^a,d   Cooper, David A ^a,b   Burger, David M ^f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood pressure (BP); Creatinine clearance; HIV; Nephrotoxicity; Pharmacokinetics (PK); Pyuria; Resource limited setting; Serum creatinine; Thailand; Therapeutic drug monitoring

Indexed keywords

COTRIMOXAZOLE; CREATININE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; PROSPECTIVE STUDY; PYURIA; BLOOD; BLOOD ANALYSIS; DRUG EFFECT; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; THAILAND;

ADULT; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PYURIA; RNA, VIRAL; THAILAND;

EID: 33749179999     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl112     Document Type: Article

References (27)

1. Kempf DJ, Marsh KC, Kumar G et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60.
2. Gulick RM, Meibohm A, Havlir D et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17: 2345-9.
3. Kopp JB, Miller KD, Mican JA et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127: 119-25.
4. Boubaker K, Sudre P, Bally F et al. Changes in renal function associated with indinavir. AIDS 1998; 12: F249-54.
5. Berns JS, Cohen RM, Silverman M et al. Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases. Am J Kidney Dis 1997; 30: 558-60.
6. Vigano A, Rombola G, Barbiano di Belgioioso G et al. Subtle occurrence of indinavir-induced acute renal insufficiency. AIDS 1998; 12: 954-5.
7. Dieleman JP, Gyssens IC, van der Ende ME et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-8.
8. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-8.
9. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-65.
10. Fletcher CV, Anderson PL, Kakuda TN et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16: 551-60.
11. Sarcletti M, Petter A, Romani N et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54: 261-70.
12. Kopp JB, Falloon J, Filie A et al. Indinavir-associated interstitial nephritis and urothelial inflammation: Clinical and cytologic findings. Clin Infect Dis 2002; 34: 1122-8.
13. Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: A pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis 2001; 38: E23.
14. Boyd MA, Srasuebkul P, Khongphattanayothin M et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther 2006; 11: 223-32.
15. Boyd MA, Siangphoe U, Ruxrungtham K et al. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Med 2005; 6: 410-20.
16. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
17. Duvivier C, Myrto A, Marcelin AG et al. Efficacy and safety of ritonavir/ indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther 2003; 8: 603-9.
18. Wasmuth JC, la Porte CJ, Schneider K et al. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR). Antivir Ther 2004; 9: 213-20.
19. Boyd M, Mootsikapun P, Burger D et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10: 301-7
20. 3: 96-week outcomes. Antivir Ther 2005; 10: 911-6.
21. Gagnon RF, Tecimer SN, Watters AK et al. The natural history of leukocyturia associated with indinavir treatment in HIV+ individuals. Am J Nephrol 2000; 20: 448-54.
22. Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, USA, October 06, 2005. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (15 January 2006, date last accessed):
23. Dragsted UB, Gerstoft J, Pedersen C et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. J Infect Dis 2003; 188: 635-42.
24. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
25. van Heeswijk RP, Veldkamp AI, Hoetelmans RM et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-9.
26. Csajka C, Marzolini C, Fattinger K et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 2004; 48: 3226-32.
27. Meraviglia P, Angeli E, Del Sorbo F et al. Risk factors for indinavir-related renal colic in HIV patients: Predictive value of indinavir dose/body mass index. AIDS 2002; 16: 2089-93.